On November 4, German Chancellor Schultz announced a new agreement with the Chinese government. The Chinese government approved Germany’s BioNTech’s covid-19 vaccine for use by foreigners in China. Scholz said the Chinese and German leaders also discussed a path for approving the BioNTech Covid-19 vaccine for the wider Chinese population.
In the first visit by a G7 leader since the coronavirus pandemic, German Chancellor Olaf Scholz led a business delegation to China. The CEOs of biopharmaceutical giants Bayer, BioNTech and Merck were among a team of 12 industry leaders on the trip.
The high-profile trip did not result in a major investment deal. The only notable deal is that China will allow expats at home to receive BioNTech’s COVID-19 vaccine, Comirnaty. The vaccine is currently available in Hong Kong, Macau and Taiwan.
When German Chancellor Scholz announced the news of his visit to China and will lead a delegation of senior business leaders to visit China, including the German biological company BioNTech, the international market was full of imagination and imagination about the resumption of the listing of Forbidden in China. expect. BioNTech has kept a low profile on all of this and declined to comment on the incident. But shares of Germany-based BioNTech SE (BNTX) surged 5.1% in premarket trading on Oct. 4, approaching a three-month high, after the German chancellor announced that China would approve Fubitx for use by foreign residents in China.
